NCT04519437View on ClinicalTrials.gov

Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19

PHASE1CompletedINTERVENTIONAL

Enrollment

974

Participants

Timeline

Start Date

July 26, 2020

Primary Completion Date

November 22, 2021

Study Completion Date

November 22, 2021

Conditions

HealthyChronic Stable Illness

Interventions

DRUG

REGN10933+REGN10987

Administered subcutaneous (SC) every 4 weeks (Q4W)

DRUG

Placebo

Administered subcutaneous (SC) every 4 weeks (Q4W)

Trial Locations (7)

33014

Regeneron Study Site, Miami

45417

Regeneron Study Site, Dayton

68502

Regeneron Study Site, Lincoln

72758

Regeneron Study Site, Rogers

78705

Regeneron Study Site, Austin

85283

Regeneron Study Site, Tempe

95864

Regeneron Study Site, Sacramento

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT04519437 - Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19 | Biotech Hunter | Biotech Hunter